Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

NCT00706706

Last updated date
Study Location
Pfizer Investigational Site
Guangzhou, Guangdong, 510060, China
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed renal cell carcinoma with metastases with a component of clear (conventional) cell histology that is not amenable to surgery.

- Evidence of unidimensionally measurable disease

- Male or female, 18 years of age or older.

- ECOG performance status 0 or 1.

- Resolution of all acute toxic effects

- Adequate organ function.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Renal cell carcinoma without any clear (conventional) cell component.


- Prior systemic therapy for metastatic disease of any kind of RCC, such as Interferon
or Interleukin, chemotherapy, hormonal, investigational or targeted therapies.
Patients may have received prior adjuvant therapy with Interferon and/or Interleukin
if recurrence occurred > 6 months after adjuvant therapy completion.


- Major surgery or radiation therapy <4 weeks of starting the study treatment. Prior
palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at
least one measurable lesion that has not been irradiated.


- NCI CTCAE grade 3 hemorrhage <4 weeks of starting the study treatment.


- Diagnosis of any second malignancy within the last 5 years, except for adequately
treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer.


- History of or known brain metastases, spinal cord compression, or carcinomatous
meningitis, or evidence of brain or leptomeningeal disease on screening CT or MRI
scan.


- Any of the following within the 12 months prior to study drug administration:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, symptomatic congestive heart failure, cerebrovascular accident or transient
ischemic attack, and 6 months for pulmonary embolism.


- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
the normal range with medication.


- Ongoing cardiac dysrhythmias, atrial fibrillation, or prolongation of the QTc interval
to >450 msec for males or >470 msec for females.


- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal
medical therapy).


- Ongoing treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO
daily for deep vein thrombosis prophylaxis is allowed).


- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
(AIDS)-related illness.


- Current treatment on another clinical trial.


- Pregnancy or breastfeeding. Female patients must be surgically sterile or be
postmenopausal, or must agree to use effective contraception during the period of
therapy. All female patients with reproductive potential must have a negative
pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically
sterile or must agree to use effective contraception during the period of therapy. The
definition of effective contraception will be based on the judgment of the principal
investigator or a designated associate.


- Other severe acute or chronic medical or psychiatric condition, or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration, or may interfere with the interpretation of study results, and in
the judgment of the investigator would make the patient inappropriate for entry into
this study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Renal Cell CarcinomaAxitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer NCT00835978
  1. Antioch, California
  2. Bakersfield, California
  3. Pleasant Hill, California
  4. Pleasant Hill, California
  5. Pleasant Hill, California
  6. San Leandro, California
  7. Tampa, Florida
  8. Indianapolis, Indiana
  9. Indianapolis, Indiana
  10. Indianapolis, Indiana
  11. Baltimore, Maryland
  12. Baltimore, Maryland
  13. Baltimore, Maryland
  14. Boston, Massachusetts
  15. Boston, Massachusetts
  16. Grand Rapids, Michigan
  17. Saint Louis, Missouri
  18. Saint Louis, Missouri
  19. Omaha, Nebraska
  20. Omaha, Nebraska
  21. Las Vegas, Nevada
  22. Cincinnati, Ohio
  23. Cincinnati, Ohio
  24. Cleveland, Ohio
  25. Columbus, Ohio
  26. Columbus, Ohio
  27. West Chester, Ohio
  28. Portland, Oregon
  29. Dallas, Texas
  30. Houston, Texas
  31. Seattle, Washington
  32. Brno, CZE
  33. Olomouc,
  34. Praha 8,
  35. Usti nad Labem,
  36. Duesseldorf,
  37. Frankfurt,
  38. Hannover,
  39. Tuebingen,
  40. Weiden,
  41. Nagoya, Aichi
  42. Sapporo, Hokkaido
  43. Sapporo, Hokkaido
  44. Kobe, Hyogo
  45. Osakasayama, Osaka
  46. Hamamatsu-City, Shizuoka
  47. Chuo-ku, Tokyo
  48. Koto-ku, Tokyo
  49. Shinjuku-ku, Tokyo
  50. Akita,
  51. Chiba,
  52. Fukuoka,
  53. Nagasaki,
  54. Tokushima,
  55. Yamagata,
  56. Obninsk, Kaluga Region
  57. Poselok Kuzmolovskiy, Vsevolozhskiy Region, Leningradskaya Oblast
  58. Moscow,
  59. Moscow,
  60. Saint-Petersburg,
  61. Saint-Petersburg,
  62. Samara,
  63. Madrid,
  64. Madrid,
  65. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaTreatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma NCT00130897
  1. Scottsdale, Arizona
  2. San Francisco, California
  3. San Francisco, California
  4. Aurora, Colorado
  5. Norwalk, Connecticut
  6. Miami, Florida
  7. Ocala, Florida
  8. Tampa, Florida
  9. Atlanta, Georgia
  10. Maywood, Illinois
  11. Indianapolis, Indiana
  12. Council Bluffs, Iowa
  13. Covington, Louisiana
  14. Gretna, Louisiana
  15. Marrero, Louisiana
  16. Metairie, Louisiana
  17. Metairie, Louisiana
  18. New Orleans, Louisiana
  19. Baltimore, Maryland
  20. Boston, Massachusetts
  21. Boston, Massachusetts
  22. Boston, Massachusetts
  23. Detroit, Michigan
  24. Minneapolis, Minnesota
  25. Southaven, Mississippi
  26. Tupelo, Mississippi
  27. Columbia, Missouri
  28. Columbia, Missouri
  29. Omaha, Nebraska
  30. Bronx, New York
  31. New York, New York
  32. New York, New York
  33. Durham, North Carolina
  34. Cleveland, Ohio
  35. Norman, Oklahoma
  36. Oklahoma City, Oklahoma
  37. Oklahoma City, Oklahoma
  38. Oklahoma City, Oklahoma
  39. Oklahoma City, Oklahoma
  40. Tulsa, Oklahoma
  41. Tulsa, Oklahoma
  42. Portland, Oregon
  43. Portland, Oregon
  44. Hershey, Pennsylvania
  45. Memphis, Tennessee
  46. Memphis, Tennessee
  47. Dallas, Texas
  48. Salt Lake City, Utah
  49. Seattle, Washington
  50. Seattle, Washington
  51. Seattle, Washington
  52. Seattle, Washington
  53. Madison, Wisconsin
  54. Buenos Aires,
  55. Buenos Aires,
  56. Buenos Aires,
  57. Randwick, New South Wales
  58. St Leonards, New South Wales
  59. Westmead, New South Wales
  60. South Brisbane, Queensland
  61. Elizabeth Vale, South Australia
  62. Woodville South, South Australia
  63. East Melbourne, Victoria
  64. Heidelburg, Victoria
  65. Perth, Western Australia
  66. Innsbruck,
  67. Wien,
  68. Bruxelles,
  69. Bruxelles,
  70. Gent,
  71. Leuven,
  72. Liege,
  73. Wilrijk,
  74. Sarajevo,
  75. Salvador, BA
  76. Belo Horizonte, MG
  77. Porto Alegre, Rio Grande do Sul
  78. Rio de Janeiro, RJ
  79. Rio de Janeiro, RJ
  80. Porto Alegre, RS
  81. Jau, SP
  82. Jaú, SP
  83. Jaú, SP
  84. São Paulo, SP
  85. São Paulo, SP
  86. São Paulo, SP
  87. Sofia,
  88. Sofia,
  89. Calgary, Alberta
  90. Edmonton, Alberta
  91. Kelowna, British Columbia
  92. Vancouver, British Columbia
  93. Victoria, British Columbia
  94. Winnipeg, Manitoba
  95. Winnnipeg, Manitoba
  96. St. John's, Newfoundland and Labrador
  97. Halifax, Nova Scotia
  98. Halifax, Nova Scotia
  99. London, Ontario
  100. Toronto, Ontario
  101. Toronto, Ontario
  102. Montreal, Quebec
  103. Montreal, Quebec
  104. Quebec,
  105. Santiago, RM
  106. Bogotá, Cundinamarca
  107. Cali,
  108. Rijeka,
  109. Split,
  110. Brno,
  111. Hradec Kralove,
  112. Praha 5,
  113. Praha 8,
  114. Guayaquil, Guayas
  115. Quito, Pichincha
  116. Cairo,
  117. Giza,
  118. Turku,
  119. Lyon, Cedex 08
  120. Saint Herblain, Cedex
  121. Strasbourg, Cedex
  122. Bordeaux,
  123. Clermont Ferand,
  124. Marseille Cedex 9,
  125. Marseille,
  126. Montpellier,
  127. Paris Cedex 13,
  128. Paris,
  129. Reims,
  130. Rennes,
  131. Tours,
  132. Vandoeuvre les Nancy,
  133. Aachen,
  134. Berlin,
  135. Dresden,
  136. Essen,
  137. Frankfurt,
  138. Freiburg,
  139. Hamburg,
  140. Hannover,
  141. Homburg/Saar,
  142. Jena,
  143. Kassel,
  144. Muenchen,
  145. Nuernberg,
  146. Rostock,
  147. Ulm,
  148. Athens, Attiki
  149. Athens,
  150. Patras,
  151. Thessaloniki,
  152. Hong Hong,
  153. Budapest,
  154. New Delhi, Delhi
  155. Pune, Maharashtra
  156. Parel, Mumbai
  157. Jaipur, Rajasthan
  158. New Delhi,
  159. Dublin 24,
  160. Dublin,
  161. Jerusalem,
  162. Tel Hashomer,
  163. Bergamo,
  164. Brescia,
  165. Cattolica (RN),
  166. Cuneo,
  167. Legnago, VR,
  168. Modena,
  169. Napoli,
  170. Padova,
  171. Parma,
  172. Pavia,
  173. Perugia,
  174. Pordenone,
  175. Rimini,
  176. Roma,
  177. Roma,
  178. Roma,
  179. Torino,
  180. Seoul,
  181. Seoul,
  182. Beirut,
  183. Petaling Jaya, Selangor
  184. Kuala Lumpur,
  185. Mexico, DF
  186. Mexico, DF
  187. Toluca, Estado de Mexico
  188. Guadalajara, Jalisco
  189. Merida, Yucatan
  190. Chihuahua,
  191. Puebla,
  192. Groningen, GR
  193. Amsterdam, NH
  194. Amsterdam,
  195. Rotterdam,
  196. Oslo,
  197. Ciudad de Panama,
  198. Panama,
  199. Lima,
  200. Lima,
  201. Quezon City,
  202. Quezon City,
  203. Gdansk,
  204. Lodz,
  205. Poznan,
  206. Warszawa,
  207. Wroclaw,
  208. Lisboa,
  209. Porto,
  210. Bucuresti,
  211. Cluj-Napoca,
  212. Obninsk, Kaluga region
  213. Chelyabinsk,
  214. Moscow,
  215. Belgrade,
  216. Singapore,
  217. Bratislava,
  218. Zilina,
  219. Ljubljana,
  220. Oviedo, Asturias
  221. L'hospitalet Del Llobregat, Barcelona
  222. Pamplona, Navarra
  223. Baracaldo, Vizcaya
  224. Barcelona,
  225. Barcelona,
  226. La Coruña,
  227. Madrid,
  228. Madrid,
  229. Madrid,
  230. Salamanca,
  231. Sevilla,
  232. Valencia,
  233. Göteborg,
  234. Lund,
  235. Stockholm,
  236. Umeå,
  237. Basel,
  238. Bellinzona,
  239. Bern,
  240. Biel,
  241. CH-4058 Basel,
  242. CH-4101 Bruderholz,
  243. CH-4410 Liesthal,
  244. Chur,
  245. Genève 14,
  246. Taipei,
  247. Taipei,
  248. Taoyun,
  249. Bangkok,
  250. Bangkok,
  251. Istanbul, Capa
  252. Istanbul, Cerrahpasa
  253. Whitchurch, Cardiff
  254. London, Se1 9rt
  255. Sutton, Surrey
  256. Leeds, West Yorkshire
  257. Belfast,
  258. Birmingham,
  259. Birmingham,
  260. Bristol,
  261. Cottingham,
  262. Edinburgh,
  263. Guildford,
  264. London,
  265. London,
  266. London,
  267. Manchester,
  268. Northwood,
  269. Nottingham,
  270. Sheffield,
  271. Southampton,
  272. Swansea,
  273. Caracas, Distrito Capital
  274. Caracas, Estado Miranda
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaSUTENT® In The First Line Treatment Of Renal Cell Carcinoma NCT00460798
ALL GENDERS
0+
years
MULTIPLE SITES
Renal Cell CarcinomaA Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. NCT00077974
  1. Duarte, California
  2. Pasadena, California
  3. San Francisco, California
  4. Boston, Massachusetts
  5. Boston, Massachusetts
  6. Boston, Massachusetts
  7. Ann Arbor, Michigan
  8. Rochester, Minnesota
  9. New York, New York
  10. New York, New York
  11. Durham, North Carolina
  12. Cleveland, Ohio
  13. Portland, Oregon
  14. Philadelphia, Pennsylvania
  15. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
Official Title  ICMJE A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study)
Brief Summary To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Carcinoma, Renal Cell
Intervention  ICMJE Drug: Sunitinib Malate (SU011248)
Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
Study Arms  ICMJE Experimental: sunitinib
single agent sunitinib, single arm
Intervention: Drug: Sunitinib Malate (SU011248)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 19, 2011)
105
Original Estimated Enrollment  ICMJE
 (submitted: June 26, 2008)
100
Actual Study Completion Date  ICMJE August 2011
Actual Primary Completion Date August 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed renal cell carcinoma with metastases with a component of clear (conventional) cell histology that is not amenable to surgery.
  • Evidence of unidimensionally measurable disease
  • Male or female, 18 years of age or older.
  • ECOG performance status 0 or 1.
  • Resolution of all acute toxic effects
  • Adequate organ function.

Exclusion Criteria:

  • Renal cell carcinoma without any clear (conventional) cell component.
  • Prior systemic therapy for metastatic disease of any kind of RCC, such as Interferon or Interleukin, chemotherapy, hormonal, investigational or targeted therapies. Patients may have received prior adjuvant therapy with Interferon and/or Interleukin if recurrence occurred > 6 months after adjuvant therapy completion.
  • Major surgery or radiation therapy <4 weeks of starting the study treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated.
  • NCI CTCAE grade 3 hemorrhage <4 weeks of starting the study treatment.
  • Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer.
  • History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease on screening CT or MRI scan.
  • Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, and 6 months for pulmonary embolism.
  • Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.
  • Ongoing cardiac dysrhythmias, atrial fibrillation, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
  • Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
  • Ongoing treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
  • Current treatment on another clinical trial.
  • Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00706706
Other Study ID Numbers  ICMJE A6181132
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP